Effects of Acamprosate on Sleep During Alcohol Withdrawal: A Double‐Blind Placebo‐Controlled Polysomnographic Study in Alcohol‐Dependent Subjects
- 14 August 2006
- journal article
- research article
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 30 (9), 1492-1499
- https://doi.org/10.1111/j.1530-0277.2006.00180.x
Abstract
Sleep disturbances are frequently encountered in alcohol-dependent patients. Drugs improving sleep during abstinence from alcohol may play an important role in the recovery process. In the present study, the effects of acamprosate, a drug successfully used in maintaining abstinence following alcohol withdrawal, were assessed by polysomnographic recordings. A parallel double-blind placebo-controlled study was conducted in 24 male DSM-IV alcohol-dependent subjects aged 35.9+/-1.2 years. Treatments (2 tablets of 333 mg acamprosate vs placebo t.i.d.) were initiated 8 days before alcohol withdrawal and continued during the 15 days following alcohol withdrawal. Polysomnographic assessments were recorded during acute withdrawal (the first 2 nights following withdrawal) and during postwithdrawal abstinence (the last 2 nights of the trial). Results show that, compared with placebo, acamprosate decreased wake time after sleep onset and increased stage 3 and REM sleep latency (all treatment effects with a p < 0.05 significance). Withdrawal effects themselves were also demonstrated as sleep efficiency (p < 0.01) and total sleep time (p < 0.05) were lower in abstinence nights versus withdrawal nights, whereas no significant treatment x withdrawal effect could be evidenced. Acamprosate was well tolerated during the entire course of the study. The present study shows that acamprosate ameliorates both sleep continuity and sleep architecture parameters classically described as disturbed in alcohol-dependent patients. From a clinical perspective, it suggests that an 8-day acamprosate prewithdrawal treatment is well tolerated and can attenuate the sleep disturbances engendered by alcohol withdrawal in alcohol-dependent subjects.Keywords
This publication has 44 references indexed in Scilit:
- Pharmacodynamic Effects of Acamprosate on Markers of Cerebral Function in Alcohol-Dependent Subjects Administered as Pretreatment and during Alcohol AbstinenceNeuropsychobiology, 2004
- Sleep Abnormalities During Abstinence in Alcohol-Dependent PatientsCNS Drugs, 2001
- Reduced Ethanol Inhibition ofN-Methyl-d-aspartate Receptors by Deletion of the NR1 C0 Domain or Overexpression of α-Actinin-2 ProteinsJournal of Biological Chemistry, 2000
- Alcohol Withdrawal SyndromeCNS Drugs, 1999
- Polysomnographic and Subjective Sleep Predictors of Alcoholic RelapseAlcohol, Clinical and Experimental Research, 1998
- Clinical Pharmacokinetics of AcamprosateClinical Pharmacokinetics, 1998
- Effects of tetrabamate and of diazepam on sleep polygraphy during subacute withdrawal in alcohol‐dependent patientsHuman Psychopharmacology: Clinical and Experimental, 1994
- Rapid Communication Chronic Ingestion of Ethanol Up‐Regulates NMDAR1 Receptor Subunit Immunoreactivity in Rat HippocampusJournal of Neurochemistry, 1994
- Assessment of Alcohol Withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA‐Ar)British Journal of Addiction, 1989
- Symptomatology in Alcoholics at Various Stages of AbstinenceAlcohol, Clinical and Experimental Research, 1985